JP Morgan Chase’s Neuropace NPCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.86M Buy
173,311
+32,170
+23% +$518K ﹤0.01% 3914
2026
Q1
$1.81M Buy
141,141
+10,215
+8% +$153K ﹤0.01% 4173
2025
Q4
$2.02M Buy
130,926
+120,657
+1,175% +$1.61M ﹤0.01% 4061
2025
Q3
$106K Sell
10,269
-1,374
-12% -$13K ﹤0.01% 5869
2025
Q2
$130K Sell
11,643
-32,149
-73% -$402K ﹤0.01% 5480
2025
Q1
$538K Sell
43,792
-21,034
-32% -$263K ﹤0.01% 4722
2024
Q4
$725K Buy
64,826
+52,829
+440% +$459K ﹤0.01% 4835
2024
Q3
$83.6K Buy
11,997
+6,181
+106% +$45.2K ﹤0.01% 5768
2024
Q2
$44K Sell
5,816
-26,299
-82% -$265K ﹤0.01% 5906
2024
Q1
$424K Buy
32,115
+20,755
+183% +$296K ﹤0.01% 4894
2023
Q4
$117K Buy
+11,360
New +$90.6K ﹤0.01% 5659
2022
Q2
Sell
-3,330
Closed -$27K 6743
2022
Q1
$27K Sell
3,330
-1,622
-33% -$14K ﹤0.01% 6005
2021
Q4
$50K Buy
4,952
+2,278
+85% +$29.6K ﹤0.01% 5943
2021
Q3
$42K Sell
2,674
-5,319
-67% -$112K ﹤0.01% 5885
2021
Q2
$191K Buy
+7,993
New +$186K ﹤0.01% 5270

Other funds holding NPCE

JP Morgan Chase's NPCE Position: Q2 2026 in Review

JP Morgan Chase increased its Neuropace (NPCE) stake by 23% in Q2 2026, buying an estimated $518K and bringing the position to 173,311 shares worth $2.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3914.

JP Morgan Chase first reported a position in NPCE in Q2 2021 and has held it in 15 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • JP Morgan Chase held 173,311 shares of Neuropace worth $2.86M as of Q2 2026.
  • JP Morgan Chase bought 32,170 Neuropace shares in Q2 2026, an estimated $518K.
  • Neuropace made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3914 holding.
  • JP Morgan Chase first reported a position in Neuropace in Q2 2021 and has held it in 15 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.